Patents by Inventor Devron Averett
Devron Averett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080090844Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.Type: ApplicationFiled: February 22, 2007Publication date: April 17, 2008Applicant: Anadys Pharmaceuticals, Inc.Inventors: Devron Averett, Stephen Webber, Joseph Lennox, Erik Rueden
-
Publication number: 20060052346Abstract: The present invention relates to a method of treating HIV infections by administering a nucleoside phosphonate derivative represented by formula (1).Type: ApplicationFiled: February 17, 2005Publication date: March 9, 2006Inventor: Devron Averett
-
Publication number: 20050182001Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.Type: ApplicationFiled: March 16, 2005Publication date: August 18, 2005Applicant: Anadys Pharmaceuticals, Inc.Inventors: Devron Averett, Stephen Webber, Joseph Lennox, Erik Rueden
-
Publication number: 20050070556Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.Type: ApplicationFiled: June 7, 2004Publication date: March 31, 2005Applicant: Anadys Pharmaceuticals, Inc.Inventors: Devron Averett, Stephen Webber, Joseph Lennox, Erik Rueden, David Clark, Alan Xiang
-
Publication number: 20050054590Abstract: This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.Type: ApplicationFiled: September 1, 2004Publication date: March 10, 2005Inventor: Devron Averett
-
Publication number: 20030207826Abstract: Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another, aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response.Type: ApplicationFiled: April 30, 2003Publication date: November 6, 2003Inventors: Robert Tam, Guangyi Wang, Devron Averett, Kandasamy Ramasamy
-
Patent number: 6642206Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: April 9, 2002Date of Patent: November 4, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kanda Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6613896Abstract: C-nucleosides are synthesized by a method in which a sugar is derivatized in a single step to provide a heterocycle at the C1 position, and then the heterocycle is aromatized in another single step. In one class of preferred embodiments a cyano sugar is converted into thiocarboxamide, and subsequently condensed to form an azole ring. In a second class of preferred embodiments a cyano sugar is condensed with an amino acid to provide the azole ring. In a third class of preferred embodiments a halo sugar is condensed with a preformed heterocycle to provide the azole ring.Type: GrantFiled: June 6, 2000Date of Patent: September 2, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Rajanikanth Bandaru, Devron Averett
-
Patent number: 6573248Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: December 31, 2001Date of Patent: June 3, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6552183Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: August 7, 2000Date of Patent: April 22, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Publication number: 20030018186Abstract: Novel monocyclic L-Nucleoside compounds have the general formula 1Type: ApplicationFiled: April 9, 2002Publication date: January 23, 2003Inventors: Kanda Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6509320Abstract: Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.Type: GrantFiled: June 15, 2000Date of Patent: January 21, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Guangyi Wang, Robert Tam, Devron Averett
-
Patent number: 6479463Abstract: Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.Type: GrantFiled: June 16, 2000Date of Patent: November 12, 2002Assignee: ICN Pharmaceuticals, Inc.Inventors: Guangyi Wang, Robert Tam, Devron Averett
-
Patent number: 6455690Abstract: Novel nucleosides having the structure of Formula 1 and Formula 2 are contemplated. In one aspect of the invention, controlled release dosage forms are particularly contemplated. Further, alternative routes of administration of the nucleosides having the structure of Formula 1 or Formula 2 are contemplated.Type: GrantFiled: June 15, 2000Date of Patent: September 24, 2002Inventors: Robert Tam, Devron Averett, Guangyi Wang, Kanda Ramasamy
-
Publication number: 20020132784Abstract: Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response.Type: ApplicationFiled: April 29, 2002Publication date: September 19, 2002Inventors: Robert Tam, Guangyi Wang, Devron Averett, Kandasamy Ramasamy
-
Patent number: 6423695Abstract: Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response.Type: GrantFiled: December 20, 1999Date of Patent: July 23, 2002Assignee: Ribapharm, Inc.Inventors: Robert Tam, Guangyi Wang, Devron Averett, Kandasamy Ramasamy
-
Publication number: 20020095033Abstract: Novel monocyclic L-Nucleoside compounds have the general formula 1Type: ApplicationFiled: December 31, 2001Publication date: July 18, 2002Applicant: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6130326Abstract: Novel monocyclic L-Nucleoside compounds have the general formula ##STR1## Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: April 14, 1999Date of Patent: October 10, 2000Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett